We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The Neutrokine-a dispute which has been pending between Human Genome Sciences (HGS) and Eli Lilly has provided the latest installment in the evolution of UK patent law
